Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant. Elacestrant is an ora...
Menarini Ricerche Announces the Latest Findings of its Vaborem™ and Quofenix™ Clinical Studies
Findings included in the abstract book of the 30 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611 in Colorectal Cancer
Study design presented at the ESMO World Congress on Gastrointestinal Cancer2020
Continuous blood glucose monitoring: the Menarini Diagnostics digital “patch” now available!
Measuring blood sugar several times a day for people with diabetes, will no longer be necessary. Menarini Diagnostics has launched GlucoMen® Day CGM, an innovative digital patch, wearable for  fourteen  days in a row, which m...
Menarini Group Completes a Solid Year of Operating Performance
Menarini Group announced its 2019 results.
Menarini Group Completes Acquisition of Stemline Therapeutics
Menarini Group today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
Page 1 of 4First   Previous   [1]  2  3  4  Next   Last